1
|
Lonial S, Richard S, Matous JV, Yee AJ, Shah U, Mehta-Shah N, Martin T, Muchtar E, Ailawadhi S, Richardson PG, Bhutani M, Perino S, Kirby J, Agafonov RV, Chaturvedi P, Class B, Schnaderbeck M, Palmer MR, Gorman C, Schoenborn-Kellenberger O, Hoerres A, Fisher SL, Pollock RM, Crystal A, Mahler M, Bardeja J. Abstract CT186: Pharmacokinetic (PK) profile of a novel IKZF1/3 degrader, CFT7455, enables significant potency advantage over other IKZF1/3 degraders in models of multiple myeloma (MM) and the results of the initial treatment cohort from a first-in-human (FIH) phase 1/2 study of CFT7455 in MM. Cancer Res 2022. [DOI: 10.1158/1538-7445.am2022-ct186] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: CFT7455 is a highly potent and novel Ikaros Family Zinc Finger Protein 1/3 (IKZF1/3) degrader. In xenograft models, CFT7455 has more potent IKZF1/3 degradation compared to other degraders. Early observations from the FIH clinical trial (NCT04756726) along with supporting translational studies are presented here.
Methods: Pre-clinical studies comparing CFT7455 and CC-92480 in both in vitro and xenograft models were performed. The pre-clinical studies’ results coincided with observations from the on-going clinical trial. The clinical trial is an open-label, Phase 1/2, multi-center, FIH study in heavily pretreated relapsed/refractory (R/R) MM and non-Hodgkin’s lymphoma (NHL) patients evaluating safety, tolerability, and PK of CFT7455. Eligible MM patients are R/R to therapy and are not candidates for regimens known to provide clinical benefit. A starting dose of 50 μg QD 21 days on/7 days off (21/7) in 28-day cycles was administered.
Results: CFT7455 and CC-92480 showed similar cereblon binding profiles and in vitro IKZF1/3 degradation kinetics, translating into sub-nanomolar GI50 values in proliferation assays across a panel of MM cell lines. In the NCI-H929 xenograft model, 100 μg/kg/day of CFT7455 resulted in durable tumor regressions, while 1000 μg/kg/day of CC-92480 gave tumor stasis. Similar results were seen in a systemic model of MM, MM1.S. Both compounds achieved >95% IKZF3 degradation in tumors 4h post dose. At 48h post dose, CFT7455 was more effective than CC-92480 in maintaining IKZF3 degradation (65% vs. 6% respectively). When levels of CFT7455 and CC-92480 in plasma and tumor were compared, CFT7455 concentrations were > DC80 in tumor 48h post dose, while CC-92480 levels were undetectable in tumor and plasma, demonstrating CFT7455 has longer exposure resulting in sustained IKZF1/3 degradation in pre-clinical models.
In cohort A, 5 heavily pre-treated MM patients (pts) received single agent CFT7455. 4 pts have received at least 3 cycles, with 2 pts receiving 5 cycles. Neutropenia (grade 4) was observed in 3/5 pts without coincident fever or infection. Additionally, a 2-4 fold accumulation in plasma CFT7455 exposure at steady state was observed. Early pharmacodynamic (PD) data demonstrates deep persistent degradation of IKZF3 (~100%) and serum free light chain reduction (up to 72%) in response to treatment. Stable disease has been observed in 34 pts, suggesting clinical benefit.
Conclusions: While CFT7455 showed clinical benefit at 50 ug with deep target degradation, neutropenia was dose limiting. PK/PD modeling suggests alternative dosing regimens may result in increased tolerability with preserved efficacy, and evaluation of them is underway. Updated results will be presented at the meeting.
Citation Format: Sagar Lonial, Shambavi Richard, Jeffrey V Matous, Andrew J. Yee, Urvi Shah, Neha Mehta-Shah, Thomas Martin, Eli Muchtar, Sikander Ailawadhi, Paul G. Richardson, Manisha Bhutani, Samantha Perino, Jason Kirby, Roman V. Agafonov, Prasoon Chaturvedi, Bradley Class, Matthew Schnaderbeck, Michael R. Palmer, Cathleen Gorman, Oliver Schoenborn-Kellenberger, Amanda Hoerres, Stewart L. Fisher, Roy M. Pollock, Adam Crystal, Michelle Mahler, Jesus Bardeja. Pharmacokinetic (PK) profile of a novel IKZF1/3 degrader, CFT7455, enables significant potency advantage over other IKZF1/3 degraders in models of multiple myeloma (MM) and the results of the initial treatment cohort from a first-in-human (FIH) phase 1/2 study of CFT7455 in MM [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr CT186.
Collapse
Affiliation(s)
- Sagar Lonial
- 1Emory University Winship Cancer institute, Atlanta, GA
| | | | - Jeffrey V Matous
- 3Sarah Cannon Research Institute, Colorado Blood Cancer Institute, Denver, CO
| | - Andrew J. Yee
- 4Massachusetts General Hospital Cancer Center, Boston, MA
| | - Urvi Shah
- 5Memorial Sloan Kettering Cancer Center, New York, NY
| | | | - Thomas Martin
- 7University of California San Francisco, San Francisco, CA
| | - Eli Muchtar
- 8Division of Hematology, Mayo Clinic Rochester, Saint Paul, MN
| | | | - Paul G. Richardson
- 10Dana-Farber/Boston Children's Cancer and Blood Disorders Ctr, Boston, MA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Jesus Bardeja
- 13Tennessee Oncology (Sarah Cannon Research Institute), Nashville, TN
| |
Collapse
|
2
|
Sowa ME, Kreger B, Baddour J, Liang Y, Simard JR, Poling L, Li P, Yu R, Hart A, Agafonov RV, Sarkissian G, Patel JS, Deibler R, Cole KS, Eron S, Cocozziello D, Rahman F, Moustakim M, Nasveschuk CG, Jackson KL, Fitzgerald M, Garza V, O’Shea M, Veits G, Yap JL, Phillips AJ, Norton E, Crystal AS, Fisher SL, Pollock RM. Abstract 2158: Preclinical evaluation of CFT1946 as a selective degrader of mutant BRAF for the treatment of BRAF driven cancers. Cancer Res 2022. [DOI: 10.1158/1538-7445.am2022-2158] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The BRAF kinase is a critical node in the MAPK signaling pathway and is mutated in approximately 8% of human cancers including melanoma (~60%), thyroid (~60%), and lung adenocarcinoma (~10%). The most common mutation in BRAF is V600E (Class I), occurring in half of malignant melanomas. This mutation hyperactivates ERK and signals as a RAF inhibitor-sensitive monomer. BRAF inhibitors including vemurafenib, dabrafenib and encorafenib have produced impressive responses in V600X patients, however resistance usually emerges within a year, including RAS mutation, BRAFV600E amplification, and BRAFV600E intragenic deletion or splice variants. These inhibitors are also ineffective against non-V600 BRAF mutants (Class II & III). To address some of these limitations we have developed CFT1946, a bifunctional degradation activating compound (BiDAC™) degrader comprising a BRAF kinase domain targeting ligand linked to a cereblon ligand. CFT1946 is capable of degrading BRAF V600E (Class I), G469A (Class II), G466V (Class III) mutations, and the p61-BRAFV600E splice variant while maintaining exquisite selectivity against the proteome including WT BRAF and CRAF. In A375 cells, CFT1946 potently degraded BRAFV600E (Emax = 26%; DC50 = 14nM at 24hr) and, inhibited ERK phosphorylation (IC50 = 11nM at 24hr) and cell growth (GI50 = 94nM at 96hr) while having no effect in the mutant KRAS driven cell line HCT116. In A375 xenografts, oral delivery of CFT1946 resulted in deeper tumor regressions when dosed at 10 mg/kg PO BID and compared favorably to a clinically relevant dose of encorafenib. We further evaluated CFT1946 in an engineered A375-BRAFV600E/NRASQ61K double mutant model of BRAF inhibitor resistance. CFT1946 was able to degrade BRAFV600E in these cells and was much more effective than encorafenib at inhibiting viability in vitro. In this model, in vivo dosing of single agent CFT1946 caused robust tumor growth inhibition and combination with the MEK inhibitor, trametinib, resulted in tumor regressions. The combination of encorafenib and trametinib showed no activity in the same model. Next, we demonstrated that CFT1946 was able to degrade additional BRAF mutant proteins including G469A (Class II), G466V (Class III), and the p61-BRAFV600E splice variant using heterologous expression in HEK293T cells. Additionally, we also showed that CFT1946, but not encorafenib, inhibited proliferation of the BRAFG466V heterozygous lung tumor cell line H1666. Based on its activity in preclinical models, including models of BRAF inhibitor resistance, and its drug-like properties we are progressing CFT1946 as a candidate for clinical development in patients with solid tumors bearing BRAF V600X mutations. Further, given CFT1946’s activity on non-V600 BRAF mutations, we are continuing to explore CFT1946 and related BiDAC degraders as therapeutic options for patients bearing Class II or Class III BRAF mutations.
Citation Format: Mathew E. Sowa, Bridget Kreger, Joelle Baddour, Yanke Liang, Jeffrey R. Simard, Laura Poling, Ping Li, Robert Yu, Ashley Hart, Roman V. Agafonov, Grace Sarkissian, Joe Sahil Patel, Richard Deibler, Kyle S. Cole, Scott Eron, David Cocozziello, Fazlur Rahman, Moses Moustakim, Christopher G. Nasveschuk, Katrina L. Jackson, Mark Fitzgerald, Victoria Garza, Morgan O’Shea, Gesine Veits, Jeremy L. Yap, Andrew J. Phillips, Elizabeth Norton, Adam S. Crystal, Stewart L. Fisher, Roy M. Pollock. Preclinical evaluation of CFT1946 as a selective degrader of mutant BRAF for the treatment of BRAF driven cancers [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 2158.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Ping Li
- 1C4 Therapeutics, Watertown, MA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Jackson KL, Agafonov RV, Carlson MW, Chaturvedi P, Cocozziello D, Cole K, Deibler R, Eron SJ, Good A, Hart AA, He M, Henderson CS, Huang H, Isasa M, Kirby RJ, Lee L, Mahler M, Moustakim M, Nasveschuk CG, Palmer M, Poling LL, Pollock RM, Schnaderbeck M, Spence S, Veits GK, Yap JL, Yin N, Zeid R, Crystal AS, Phillips AJ, Fisher SL. Abstract ND09: The discovery and characterization of CFT8634: A potent and selective degrader of BRD9 for the treatment of SMARCB1-perturbed cancers. Cancer Res 2022. [DOI: 10.1158/1538-7445.am2022-nd09] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: The chromatin factor BRD9 is a genetic dependency in some cancers, often referred to as SMARCB1-perturbed cancers. Two types of genetic alterations result in SMARCB1 perturbation: SS18-SSX gene fusion and SMARCB1 loss-of-function mutations. In synovial sarcoma, a rare and aggressive soft tissue malignancy comprising approximately 10% of all soft tissue sarcomas, the presence of the SS18-SSX fusion gene drives the disruption of SMARCB1 function and leads to a synthetic lethal dependence on BRD9. In SMARCB1-null solid tumors, for example malignant rhabdoid tumors (MRT), poorly differentiated chordomas, and epithelioid sarcomas, the absence of SMARCB1 protein results in a similar BRD9 dependence. Thus, in SMARCB1-perturbed cancers, including synovial sarcoma and SMARCB1-null cancers, degradation of BRD9 is hypothesized to result in an anticancer effect. CFT8634 is an orally bioavailable heterobifunctional degrader that induces ternary complex formation with BRD9 and an E3 ligase, leading to the ubiquitination of BRD9 and its subsequent degradation by the proteasome.
Results: Here we describe the chemical structure of CFT8634 and an overview of the medicinal chemistry path leading to its discovery. In vitro, CFT8634 promotes rapid, potent, deep, and selective degradation of BRD9 with a half-maximal degradation concentration (DC50) of 2 nM in a synovial sarcoma cell line. In long-term growth assays, CFT8634 is effective at impairing cell growth in a concentration-dependent manner specifically in SMARCB1-perturbed contexts. In vivo, oral dosing of CFT8634 in xenograft models of SMARCB1-perturbed cancers leads to robust and dose-dependent degradation of BRD9, which translates to significant and dose-dependent inhibition of tumor growth in preclinical xenograft models.
Conclusion: The preclinical data presented herein support the clinical development of CFT8634 for the treatment of synovial sarcoma and SMARCB1-null tumors.
Citation Format: Katrina L. Jackson, Roman V. Agafonov, Mark W. Carlson, Prasoon Chaturvedi, David Cocozziello, Kyle Cole, Richard Deibler, Scott J. Eron, Andrew Good, Ashley A. Hart, Minsheng He, Christina S. Henderson, Hongwei Huang, Marta Isasa, R. Jason Kirby, Linda Lee, Michelle Mahler, Moses Moustakim, Christopher G. Nasveschuk, Michael Palmer, Laura L. Poling, Roy M. Pollock, Matthew Schnaderbeck, Stan Spence, Gesine K. Veits, Jeremy L. Yap, Ning Yin, Rhamy Zeid, Adam S. Crystal, Andrew J. Phillips, Stewart L. Fisher. The discovery and characterization of CFT8634: A potent and selective degrader of BRD9 for the treatment of SMARCB1-perturbed cancers [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr ND09.
Collapse
|
4
|
Henderson JA, Eron SJ, Good A, Kirby RJ, Perino S, Agafonov RV, Chaturvedi P, Class B, Cocozziello D, Hart AA, Henderson CS, Isasa M, Ladd B, Schnaderbeck M, Mahler M, Crystal AS, Pollock RM, Nasveschuk CG, Phillips AJ, Fisher SL, Proia DA. Abstract ND13: The discovery and characterization of CFT7455: A potent and selective degrader of IKZF1/3 for the treatment of relapsed/refractory multiple myeloma. Cancer Res 2022. [DOI: 10.1158/1538-7445.am2022-nd13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Ikaros family zinc finger protein 1 and 3 (IKZF1/3) are essential transcription factors (TF) for terminal differentiation of B and T cells. Depletion of IKZF1/3 inhibits the growth of multiple myeloma (MM) cells, confirming their dependency on IKZF1/3. IMiDs (lenalidomide, pomalidomide) are effective therapies for treatment of MM and promote degradation of IKZF1/3 via their interaction with CRL4-CRBN E3 ligase. However, most patients treated with lenalidomide or pomalidomide eventually develop progressive disease due to acquired resistance, underscoring the unmet medical need. CFT7455 is a novel IKZF1/3 degrader optimized for high binding affinity to cereblon (CRBN), rapid and deep IKZF1/3 degradation, and potent dose-dependent efficacy in vivo.
Results: A series of novel benzoimidazolone-based CRBN ligands with potent binding affinity were discovered and their binding modes were informed by CRBN co-crystal structures. Although the benzoimidazolone-based CRBN binders did not exhibit IKZF1/3 degradation activity, structural insights into their unique binding modes and knowledge of the IKZF1/3 degradation pharmacophore were combined to enable identification of a novel benzoisoindolone-based ligand that exhibited a 10-fold potency increase in biochemical CRBN binding and a 30-fold potency increase in H929 MM cell growth inhibition when compared to lenalidomide. Additional rounds of structure-based drug design, degradation and phenotypic profiling led to the discovery of CFT7455, a highly potent, selective and orally bioavailable degrader of IKZF1/3. CFT7455 demonstrated an 800 and 1600-fold improvement in CRBN binding compared to pomalidomide in biochemical and cellular NanoBRET assays, respectively. In H929 MM cells expressing HiBiT-tagged IKZF1, CFT7455 induced >75% degradation of IKZF1 within 1.5 hrs. The high binding affinity and degradation catalysis shown with CFT7455 enabled potent antiproliferative activity across a panel of MM cell lines, as well as H929 cells made resistant to IMiDs. In vivo, CFT7455 catalyzed deep and durable degradation of IKZF3, translating into potent antitumor activity in multiple myeloma xenograft models. CFT7455 also retained its activity in models resistant or insensitive to clinically approved IMiDs as single agent or in combination with standard of care agent dexamethasone.
Conclusion: Overall, CFT7455 is a next generation IKZF1/3 degrader, with improved potency and anticancer efficacy in preclinical models compared to existing IMiDs. These features make CFT7455 an exciting drug candidate, as a single agent or for use in combination. CFT7455 is currently being studied in a Ph1 clinical trial.
Citation Format: James A. Henderson, Scott J. Eron, Andrew Good, R Jason Kirby, Samantha Perino, Roman V. Agafonov, Prasoon Chaturvedi, Bradley Class, David Cocozziello, Ashley A. Hart, Christina S. Henderson, Marta Isasa, Brendon Ladd, Matt Schnaderbeck, Michelle Mahler, Adam S. Crystal, Roy M. Pollock, Christopher G. Nasveschuk, Andrew J. Phillips, Stewart L. Fisher, David A. Proia. The discovery and characterization of CFT7455: A potent and selective degrader of IKZF1/3 for the treatment of relapsed/refractory multiple myeloma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr ND13.
Collapse
|
5
|
Eron SJ, Huang H, Agafonov RV, Fitzgerald ME, Patel J, Michael RE, Lee TD, Hart AA, Shaulsky J, Nasveschuk CG, Phillips AJ, Fisher SL, Good A. Structural Characterization of Degrader-Induced Ternary Complexes Using Hydrogen-Deuterium Exchange Mass Spectrometry and Computational Modeling: Implications for Structure-Based Design. ACS Chem Biol 2021; 16:2228-2243. [PMID: 34582690 DOI: 10.1021/acschembio.1c00376] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
The field of targeted protein degradation (TPD) has grown exponentially over the past decade with the goal of developing therapies that mark proteins for destruction leveraging the ubiquitin-proteasome system. One common approach to achieve TPD is to employ a heterobifunctional molecule, termed as a degrader, to recruit the protein target of interest to the E3 ligase machinery. The resultant generation of an intermediary ternary complex (target-degrader-ligase) is pivotal in the degradation process. Understanding the ternary complex geometry offers valuable insight into selectivity, catalytic efficiency, linker chemistry, and rational degrader design. In this study, we utilize hydrogen-deuterium exchange mass spectrometry (HDX-MS) to identify degrader-induced protein-protein interfaces. We then use these data in conjunction with constrained protein docking to build three-dimensional models of the ternary complex. The approach was used to characterize complex formation between the E3 ligase CRBN and the first bromodomain of BRD4, a prominent oncology target. We show marked differences in the ternary complexes formed in solution based on distinct patterns of deuterium uptake for two degraders, CFT-1297 and dBET6. CFT-1297, which exhibited positive cooperativity, altered the deuterium uptake profile revealing the degrader-induced protein-protein interface of the ternary complex. For CFT-1297, the ternary complexes generated by the highest scoring HDX-constrained docking models differ markedly from those observed in the published crystal structures. These results highlight the potential utility of HDX-MS to provide rapidly accessible structural insights into degrader-induced protein-protein interfaces in solution. They further suggest that degrader ternary complexes exhibit significant conformation flexibility and that biologically relevant complexes may well not exhibit the largest interaction surfaces between proteins. Taken together, the results indicate that methods capable of incorporating linker conformation uncertainty may prove an important component in degrader design moving forward. In addition, the development of scoring functions modified to handle interfaces with no evolved complementarity, for example, through consideration of high levels of water infiltration, may prove valuable. Furthermore, the use of crystal structures as validation tools for novel degrader methods needs to be considered with caution.
Collapse
Affiliation(s)
- Scott J. Eron
- C4 Therapeutics, Inc., 490 Arsenal Way Suite 200, Watertown, Massachusetts 02472, United States
| | - Hongwei Huang
- C4 Therapeutics, Inc., 490 Arsenal Way Suite 200, Watertown, Massachusetts 02472, United States
| | - Roman V. Agafonov
- C4 Therapeutics, Inc., 490 Arsenal Way Suite 200, Watertown, Massachusetts 02472, United States
| | - Mark E. Fitzgerald
- C4 Therapeutics, Inc., 490 Arsenal Way Suite 200, Watertown, Massachusetts 02472, United States
| | - Joe Patel
- C4 Therapeutics, Inc., 490 Arsenal Way Suite 200, Watertown, Massachusetts 02472, United States
| | - Ryan E. Michael
- C4 Therapeutics, Inc., 490 Arsenal Way Suite 200, Watertown, Massachusetts 02472, United States
| | - Tobie D. Lee
- C4 Therapeutics, Inc., 490 Arsenal Way Suite 200, Watertown, Massachusetts 02472, United States
| | - Ashley A. Hart
- C4 Therapeutics, Inc., 490 Arsenal Way Suite 200, Watertown, Massachusetts 02472, United States
| | - Jodi Shaulsky
- Dassault Systèmes BIOVIA, 5005 Wateridge Vista Dr, San Diego, California 92121, United States
| | | | - Andrew J. Phillips
- C4 Therapeutics, Inc., 490 Arsenal Way Suite 200, Watertown, Massachusetts 02472, United States
| | - Stewart L. Fisher
- C4 Therapeutics, Inc., 490 Arsenal Way Suite 200, Watertown, Massachusetts 02472, United States
| | - Andrew Good
- C4 Therapeutics, Inc., 490 Arsenal Way Suite 200, Watertown, Massachusetts 02472, United States
| |
Collapse
|
6
|
Sun D, Nikonova AS, Zhang P, Deneka AY, Fitzgerald ME, Michael RE, Lee L, Lilly AC, Fisher SL, Phillips AJ, Nasveschuk CG, Proia DA, Tu Z, Golemis EA. Evaluation of the Small-molecule BRD4 Degrader CFT-2718 in Small-cell Lung Cancer and Pancreatic Cancer Models. Mol Cancer Ther 2021; 20:1367-1377. [PMID: 34045230 DOI: 10.1158/1535-7163.mct-20-0831] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2020] [Revised: 02/25/2021] [Accepted: 04/05/2021] [Indexed: 01/03/2023]
Abstract
Targeted, catalytic degradation of oncoproteins using heterobifunctional small molecules is an attractive modality, particularly for hematologic malignancies, which are often initiated by aberrant transcription factors and are challenging to drug with inhibitors. BRD4, a member of the bromodomain and extraterminal family, is a core transcriptional and epigenetic regulator that recruits the P-TEFb complex, which includes Cdk9 and cyclin T, to RNA polymerase II (pol II). Together, BRD4 and CDK9 phosphorylate serine 2 (pSer2) of heptad repeats in the C-terminal domain of RPB1, the large subunit of pol II, promote transcriptional elongation. Small-molecule degraders of BRD4 have shown encouraging efficacy in preclinical models for several tumor types but less efficacy in other cancers including small-cell lung cancer (SCLC) and pancreatic cancer. Here, we evaluated CFT-2718, a new BRD4-targeting degrader with enhanced catalytic activity and in vivo properties. In vivo, CFT-2718 has significantly greater efficacy than the CDK9 inhibitor dinaciclib in reducing growth of the LX-36 SCLC patient-derived xenograft (PDX) model and performed comparably to dinaciclib in limiting growth of the PNX-001 pancreatic PDX model. In vitro, CFT-2718 reduced cell viability in four SCLC and two pancreatic cancer models. In SCLC models, this activity significantly exceeded that of dinaciclib; furthermore, CFT-2718 selectively increased the expression of cleaved PARP, an indicator of apoptosis. CFT-2718 caused rapid BRD4 degradation and reduced levels of total and pSer2 RPB1 protein. These and other findings suggest that BRD-mediated transcriptional suppression merits further exploration in the setting of SCLC.
Collapse
Affiliation(s)
- Danlin Sun
- Program in Molecular Therapeutics, Fox Chase Cancer Center, Philadelphia, Pennsylvania.,Institute of Life Sciences, Jiangsu University, Jinkou District, Zhenjiang, Jiangsu, China
| | - Anna S Nikonova
- Program in Molecular Therapeutics, Fox Chase Cancer Center, Philadelphia, Pennsylvania
| | - Peishan Zhang
- Program in Molecular Therapeutics, Fox Chase Cancer Center, Philadelphia, Pennsylvania.,Institute of Life Sciences, Jiangsu University, Jinkou District, Zhenjiang, Jiangsu, China
| | - Alexander Y Deneka
- Program in Molecular Therapeutics, Fox Chase Cancer Center, Philadelphia, Pennsylvania
| | | | | | - Linda Lee
- C4 Therapeutics, Inc., Watertown, Massachusetts
| | - Anna C Lilly
- Program in Molecular Therapeutics, Fox Chase Cancer Center, Philadelphia, Pennsylvania.,Drexel University College of Medicine, Philadelphia, Pennsylvania
| | | | | | | | | | - Zhigang Tu
- Institute of Life Sciences, Jiangsu University, Jinkou District, Zhenjiang, Jiangsu, China.
| | - Erica A Golemis
- Program in Molecular Therapeutics, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
| |
Collapse
|
7
|
Castaldi MP, Fisher SL. Advances in Protein Degradation. SLAS Discov 2021; 26:471-473. [PMID: 33780295 DOI: 10.1177/24725552211001823] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
|
8
|
Vieux EF, Agafonov RV, Emerson L, Isasa M, Deibler RW, Simard JR, Cocozziello D, Ladd B, Lee L, Li H, Archer S, Fitzgerald M, Michael R, Nasveschuk CG, Park ES, Kern G, Proia DA, Phillips AJ, Fisher SL. A Method for Determining the Kinetics of Small-Molecule-Induced Ubiquitination. SLAS Discov 2021; 26:547-559. [PMID: 33780296 DOI: 10.1177/24725552211000673] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Recent advances in targeted protein degradation have enabled chemical hijacking of the ubiquitin-proteasome system to treat disease. The catalytic rate of cereblon (CRBN)-dependent bifunctional degradation activating compounds (BiDAC), which recruit CRBN to a chosen target protein, resulting in its ubiquitination and proteasomal degradation, is an important parameter to consider during the drug discovery process. In this work, an in vitro system was developed to measure the kinetics of BRD4 bromodomain 1 (BD1) ubiquitination by fitting an essential activator kinetic model to these data. The affinities between BiDACs, BD1, and CRBN in the binary complex, ternary complex, and full ubiquitination complex were characterized. Together, this work provides a new tool for understanding and optimizing the catalytic and thermodynamic properties of BiDACs.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | - Linda Lee
- C4 Therapeutics Inc., Watertown, MA, USA
| | - Heng Li
- C4 Therapeutics Inc., Watertown, MA, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Simard JR, Lee L, Vieux E, Improgo R, Tieu T, Phillips AJ, Fisher SL, Pollock RM, Park E. High-Throughput Quantitative Assay Technologies for Accelerating the Discovery and Optimization of Targeted Protein Degradation Therapeutics. SLAS Discov 2021; 26:503-517. [PMID: 33430712 DOI: 10.1177/2472555220985049] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
The aberrant regulation of protein expression and function can drastically alter cellular physiology and lead to numerous pathophysiological conditions such as cancer, inflammatory diseases, and neurodegeneration. The steady-state expression levels of endogenous proteins are controlled by a balance of de novo synthesis rates and degradation rates. Moreover, the levels of activated proteins in signaling cascades can be further modulated by a variety of posttranslational modifications and protein-protein interactions. The field of targeted protein degradation is an emerging area for drug discovery in which small molecules are used to recruit E3 ubiquitin ligases to catalyze the ubiquitination and subsequent degradation of disease-causing target proteins by the proteasome in both a dose- and time-dependent manner. Traditional approaches for quantifying protein level changes in cells, such as Western blots, are typically low throughput with limited quantification, making it hard to drive the rapid development of therapeutics that induce selective, rapid, and sustained protein degradation. In the last decade, a number of techniques and technologies have emerged that have helped to accelerate targeted protein degradation drug discovery efforts, including the use of fluorescent protein fusions and reporter tags, flow cytometry, time-resolved fluorescence energy transfer (TR-FRET), and split luciferase systems. Here we discuss the advantages and disadvantages associated with these technologies and their application to the development and optimization of degraders as therapeutics.
Collapse
Affiliation(s)
| | - Linda Lee
- C4 Therapeutics, Inc., Watertown, MA, USA
| | | | | | - Trang Tieu
- C4 Therapeutics, Inc., Watertown, MA, USA
| | | | | | | | | |
Collapse
|
10
|
Michalska K, Gale J, Joachimiak G, Chang C, Hatzos-Skintges C, Nocek B, Johnston SE, Bigelow L, Bajrami B, Jedrzejczak RP, Wellington S, Hung DT, Nag PP, Fisher SL, Endres M, Joachimiak A. Conservation of the structure and function of bacterial tryptophan synthases. IUCrJ 2019; 6:649-664. [PMID: 31316809 PMCID: PMC6608616 DOI: 10.1107/s2052252519005955] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 01/25/2019] [Accepted: 04/29/2019] [Indexed: 06/10/2023]
Abstract
Tryptophan biosynthesis is one of the most characterized processes in bacteria, in which the enzymes from Salmonella typhimurium and Escherichia coli serve as model systems. Tryptophan synthase (TrpAB) catalyzes the final two steps of tryptophan biosynthesis in plants, fungi and bacteria. This pyridoxal 5'-phosphate (PLP)-dependent enzyme consists of two protein chains, α (TrpA) and β (TrpB), functioning as a linear αββα heterotetrameric complex containing two TrpAB units. The reaction has a complicated, multistep mechanism resulting in the β-replacement of the hydroxyl group of l-serine with an indole moiety. Recent studies have shown that functional TrpAB is required for the survival of pathogenic bacteria in macrophages and for evading host defense. Therefore, TrpAB is a promising target for drug discovery, as its orthologs include enzymes from the important human pathogens Streptococcus pneumoniae, Legionella pneumophila and Francisella tularensis, the causative agents of pneumonia, legionnaires' disease and tularemia, respectively. However, specific biochemical and structural properties of the TrpABs from these organisms have not been investigated. To fill the important phylogenetic gaps in the understanding of TrpABs and to uncover unique features of TrpAB orthologs to spearhead future drug-discovery efforts, the TrpABs from L. pneumophila, F. tularensis and S. pneumoniae have been characterized. In addition to kinetic properties and inhibitor-sensitivity data, structural information gathered using X-ray crystallo-graphy is presented. The enzymes show remarkable structural conservation, but at the same time display local differences in both their catalytic and allosteric sites that may be responsible for the observed differences in catalysis and inhibitor binding. This functional dissimilarity may be exploited in the design of species-specific enzyme inhibitors.
Collapse
Affiliation(s)
- Karolina Michalska
- Center for Structural Genomics of Infectious Diseases, University of Chicago, Chicago, IL 60367, USA
- Structural Biology Center, Biosciences Division, Argonne National Laboratory, Argonne, IL 60439, USA
- Midwest Center for Structural Genomics, Biosciences Division, Argonne National Laboratory, Argonne, IL 60439, USA
| | - Jennifer Gale
- Broad Institute of MIT and Harvard, Cambridge, MA 02141, USA
| | - Grazyna Joachimiak
- Midwest Center for Structural Genomics, Biosciences Division, Argonne National Laboratory, Argonne, IL 60439, USA
| | - Changsoo Chang
- Center for Structural Genomics of Infectious Diseases, University of Chicago, Chicago, IL 60367, USA
- Structural Biology Center, Biosciences Division, Argonne National Laboratory, Argonne, IL 60439, USA
- Midwest Center for Structural Genomics, Biosciences Division, Argonne National Laboratory, Argonne, IL 60439, USA
| | - Catherine Hatzos-Skintges
- Center for Structural Genomics of Infectious Diseases, University of Chicago, Chicago, IL 60367, USA
| | - Boguslaw Nocek
- Center for Structural Genomics of Infectious Diseases, University of Chicago, Chicago, IL 60367, USA
- Structural Biology Center, Biosciences Division, Argonne National Laboratory, Argonne, IL 60439, USA
- Midwest Center for Structural Genomics, Biosciences Division, Argonne National Laboratory, Argonne, IL 60439, USA
| | | | - Lance Bigelow
- Midwest Center for Structural Genomics, Biosciences Division, Argonne National Laboratory, Argonne, IL 60439, USA
| | - Besnik Bajrami
- Broad Institute of MIT and Harvard, Cambridge, MA 02141, USA
| | - Robert P. Jedrzejczak
- Center for Structural Genomics of Infectious Diseases, University of Chicago, Chicago, IL 60367, USA
- Structural Biology Center, Biosciences Division, Argonne National Laboratory, Argonne, IL 60439, USA
- Midwest Center for Structural Genomics, Biosciences Division, Argonne National Laboratory, Argonne, IL 60439, USA
| | | | - Deborah T. Hung
- Broad Institute of MIT and Harvard, Cambridge, MA 02141, USA
| | - Partha P. Nag
- Broad Institute of MIT and Harvard, Cambridge, MA 02141, USA
| | | | - Michael Endres
- Midwest Center for Structural Genomics, Biosciences Division, Argonne National Laboratory, Argonne, IL 60439, USA
| | - Andrzej Joachimiak
- Center for Structural Genomics of Infectious Diseases, University of Chicago, Chicago, IL 60367, USA
- Structural Biology Center, Biosciences Division, Argonne National Laboratory, Argonne, IL 60439, USA
- Midwest Center for Structural Genomics, Biosciences Division, Argonne National Laboratory, Argonne, IL 60439, USA
- Department of Biochemistry and Molecular Biology, University of Chicago, Chicago, IL 60367, USA
| |
Collapse
|
11
|
Michalska K, Wellington S, Nag PP, Jedrzejczak R, Maltseva NI, Fisher SL, Schreiber SL, Hung DT, Joachimiak A. Structural Insight into Allosteric Inhibition of
Mycobacterium tuberculosis
Tryptophan Synthase. FASEB J 2018. [DOI: 10.1096/fasebj.31.1_supplement.765.12] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Karolina Michalska
- Center for Structural Genomics of Infectious DiseasesUniversity of ChicagoChicagoIL
| | - Samantha Wellington
- Dep. of Molecular Biology and Center for Computational and Integrative BiologyMassachusetts General HospitalBostonMA
- Dep. of Microbiology and ImmunobiologyHarvard Medical SchoolBostonMA
- Broad Institute of MIT and HarvardCambridgeMA
| | | | - Robert Jedrzejczak
- Center for Structural Genomics of Infectious DiseasesUniversity of ChicagoChicagoIL
| | - Natalia I. Maltseva
- Center for Structural Genomics of Infectious DiseasesUniversity of ChicagoChicagoIL
| | | | - Stuart L. Schreiber
- Dep. of Chemistry and Chemical BiologyHarvard UniversityCambridgeMA
- Broad Institute of MIT and HarvardCambridgeMA
| | - Deborah T. Hung
- Dep. of Molecular Biology and Center for Computational and Integrative BiologyMassachusetts General HospitalBostonMA
- Dep. of Microbiology and ImmunobiologyHarvard Medical SchoolBostonMA
- Broad Institute of MIT and HarvardCambridgeMA
| | - Andrzej Joachimiak
- Dep. of Biochemistry and Molecular BiologyUniversity of ChicagoChicagoIL
- Center for Structural Genomics of Infectious DiseasesUniversity of ChicagoChicagoIL
| |
Collapse
|
12
|
Joachimiak A, Wellington S, Nag PP, Jedrzejczak R, Maltseva NI, Fisher SL, Schreiber SL, Hung DT, Michalska K. Structural insight into allosteric inhibition of Mycobacterium tuberculosis tryptophan synthase. Acta Crystallogr A Found Adv 2017. [DOI: 10.1107/s0108767317095824] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
13
|
Michalska K, Wellington S, Nag PP, Jedrzejczak R, Maltseva NI, Fisher SL, Schreiber SL, Hung DT, Joachimiak A. Structure of Mycobacterium tuberculosis tryptophan synthase: a model system for allosteric inhibition. Acta Crystallogr A Found Adv 2017. [DOI: 10.1107/s0108767317097161] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
14
|
Daryaee F, Zhang Z, Gogarty KR, Li Y, Merino J, Fisher SL, Tonge PJ. A quantitative mechanistic PK/PD model directly connects Btk target engagement and in vivo efficacy. Chem Sci 2017; 8:3434-3443. [PMID: 28507715 PMCID: PMC5417014 DOI: 10.1039/c6sc03306g] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2016] [Accepted: 03/10/2017] [Indexed: 12/13/2022] Open
Abstract
Correlating target engagement with in vivo drug activity remains a central challenge in efforts to improve the efficiency of drug discovery. Previously we described a mechanistic pharmacokinetic-pharmacodynamic (PK/PD) model that used drug-target binding kinetics to successfully predict the in vivo efficacy of antibacterial compounds in models of Pseudomonas aeruginosa and Staphylococcus aureus infection. In the present work we extend this model to quantitatively correlate the engagement of Bruton's tyrosine kinase (Btk) by the covalent inhibitor CC-292 with the ability of this compound to reduce ankle swelling in an animal model of arthritis. The modeling studies include the rate of Btk turnover and reveal the vulnerability of Btk to engagement by CC-292.
Collapse
Affiliation(s)
- Fereidoon Daryaee
- Institute for Chemical Biology & Drug Discovery , Department of Chemistry , Stony Brook University , Stony Brook , NY 11794-3400 , USA .
| | - Zhuo Zhang
- Institute for Chemical Biology & Drug Discovery , Department of Chemistry , Stony Brook University , Stony Brook , NY 11794-3400 , USA .
| | - Kayla R Gogarty
- Institute for Chemical Biology & Drug Discovery , Department of Chemistry , Stony Brook University , Stony Brook , NY 11794-3400 , USA .
| | - Yong Li
- Institute for Chemical Biology & Drug Discovery , Department of Chemistry , Stony Brook University , Stony Brook , NY 11794-3400 , USA .
| | - Jonathan Merino
- Institute for Chemical Biology & Drug Discovery , Department of Chemistry , Stony Brook University , Stony Brook , NY 11794-3400 , USA .
| | | | - Peter J Tonge
- Institute for Chemical Biology & Drug Discovery , Department of Chemistry , Stony Brook University , Stony Brook , NY 11794-3400 , USA .
| |
Collapse
|
15
|
Daryaee F, Chang A, Schiebel J, Lu Y, Zhang Z, Kapilashrami K, Walker SG, Kisker C, Sotriffer CA, Fisher SL, Tonge PJ. Correlating Drug-Target Kinetics and In vivo Pharmacodynamics: Long Residence Time Inhibitors of the FabI Enoyl-ACP Reductase. Chem Sci 2016; 7:5945-5954. [PMID: 27547299 PMCID: PMC4988406 DOI: 10.1039/c6sc01000h] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2016] [Accepted: 05/20/2016] [Indexed: 01/20/2023] Open
Abstract
Drug-target kinetics enable time-dependent changes in target engagement to be quantified as a function of drug concentration. When coupled to drug pharmacokinetics (PK), drug-target kinetics can thus be used to predict in vivo pharmacodynamics (PD). Previously we described a mechanistic PK/PD model that successfully predicted the antibacterial activity of an LpxC inhibitor in a model of Pseudomonas aeruginosa infection. In the present work we demonstrate that the same approach can be used to predict the in vivo activity of an enoyl-ACP reductase (FabI) inhibitor in a model of methicillin-resistant Staphylococcus aureus (MRSA) infection. This is significant because the LpxC inhibitors are cidal, whereas the FabI inhibitors are static. In addition P. aeruginosa is a Gram-negative organism whereas MRSA is Gram-positive. Thus this study supports the general applicability of our modeling approach across antibacterial space.
Collapse
Affiliation(s)
- Fereidoon Daryaee
- Institute for Chemical Biology & Drug Discovery
, Department of Chemistry
, Stony Brook University
,
Stony Brook
, NY 11794-3400
, USA
.
;
| | - Andrew Chang
- Institute for Chemical Biology & Drug Discovery
, Department of Chemistry
, Stony Brook University
,
Stony Brook
, NY 11794-3400
, USA
.
;
| | - Johannes Schiebel
- Rudolf Virchow Center for Experimental Biomedicine
, Institute for Structural Biology
, University of Würzburg
,
D-97080 Würzburg
, Germany
- Institute of Pharmacy and Food Chemistry
, University of Würzburg
,
D-97074 Würzburg
, Germany
| | - Yang Lu
- Institute for Chemical Biology & Drug Discovery
, Department of Chemistry
, Stony Brook University
,
Stony Brook
, NY 11794-3400
, USA
.
;
| | - Zhuo Zhang
- Institute for Chemical Biology & Drug Discovery
, Department of Chemistry
, Stony Brook University
,
Stony Brook
, NY 11794-3400
, USA
.
;
| | - Kanishk Kapilashrami
- Institute for Chemical Biology & Drug Discovery
, Department of Chemistry
, Stony Brook University
,
Stony Brook
, NY 11794-3400
, USA
.
;
| | - Stephen G. Walker
- Institute for Chemical Biology & Drug Discovery
, Department of Oral Biology and Pathology
, Stony Brook University
,
Stony Brook
, NY 11794-3400
, USA
| | - Caroline Kisker
- Rudolf Virchow Center for Experimental Biomedicine
, Institute for Structural Biology
, University of Würzburg
,
D-97080 Würzburg
, Germany
| | - Christoph A. Sotriffer
- Institute of Pharmacy and Food Chemistry
, University of Würzburg
,
D-97074 Würzburg
, Germany
| | | | - Peter J. Tonge
- Institute for Chemical Biology & Drug Discovery
, Department of Chemistry
, Stony Brook University
,
Stony Brook
, NY 11794-3400
, USA
.
;
| |
Collapse
|
16
|
Wagner FF, Lundh M, Kaya T, McCarren P, Zhang YL, Chattopadhyay S, Gale JP, Galbo T, Fisher SL, Meier BC, Vetere A, Richardson S, Morgan NG, Christensen DP, Gilbert TJ, Hooker JM, Leroy M, Walpita D, Mandrup-Poulsen T, Wagner BK, Holson EB. An Isochemogenic Set of Inhibitors To Define the Therapeutic Potential of Histone Deacetylases in β-Cell Protection. ACS Chem Biol 2016; 11:363-74. [PMID: 26640968 DOI: 10.1021/acschembio.5b00640] [Citation(s) in RCA: 68] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
Modulation of histone deacetylase (HDAC) activity has been implicated as a potential therapeutic strategy for multiple diseases. However, it has been difficult to dissect the role of individual HDACs due to a lack of selective small-molecule inhibitors. Here, we report the synthesis of a series of highly potent and isoform-selective class I HDAC inhibitors, rationally designed by exploiting minimal structural changes to the clinically experienced HDAC inhibitor CI-994. We used this toolkit of isochemogenic or chemically matched inhibitors to probe the role of class I HDACs in β-cell pathobiology and demonstrate for the first time that selective inhibition of an individual HDAC isoform retains beneficial biological activity and mitigates mechanism-based toxicities. The highly selective HDAC3 inhibitor BRD3308 suppressed pancreatic β-cell apoptosis induced by inflammatory cytokines, as expected, or now glucolipotoxic stress, and increased functional insulin release. In addition, BRD3308 had no effect on human megakaryocyte differentiation, while inhibitors of HDAC1 and 2 were toxic. Our findings demonstrate that the selective inhibition of HDAC3 represents a potential path forward as a therapy to protect pancreatic β-cells from inflammatory cytokines and nutrient overload in diabetes.
Collapse
Affiliation(s)
- Florence F. Wagner
- Stanley
Center for Psychiatric Research, Broad Institute of Harvard and MIT, Cambridge, Massachusetts 02142, United States
| | - Morten Lundh
- Center
for the Science of Therapeutics, Broad Institute of Harvard and MIT, Cambridge, Massachusetts 02142, United States
- Department
of Biomedical Sciences, University of Copenhagen, Copenhagen 1165, Denmark
| | - Taner Kaya
- Stanley
Center for Psychiatric Research, Broad Institute of Harvard and MIT, Cambridge, Massachusetts 02142, United States
| | - Patrick McCarren
- Center
for the Science of Therapeutics, Broad Institute of Harvard and MIT, Cambridge, Massachusetts 02142, United States
| | - Yan-Ling Zhang
- Stanley
Center for Psychiatric Research, Broad Institute of Harvard and MIT, Cambridge, Massachusetts 02142, United States
| | - Shrikanta Chattopadhyay
- Center
for the Science of Therapeutics, Broad Institute of Harvard and MIT, Cambridge, Massachusetts 02142, United States
| | - Jennifer P. Gale
- Stanley
Center for Psychiatric Research, Broad Institute of Harvard and MIT, Cambridge, Massachusetts 02142, United States
| | - Thomas Galbo
- Department
of Internal Medicine, Yale University, New Haven, Connecticut 06520, United States
| | - Stewart L. Fisher
- SL Fisher Consulting, LLC, PO Box 3052, Framingham, Massachusetts 01701, United States
| | - Bennett C. Meier
- Center
for the Science of Therapeutics, Broad Institute of Harvard and MIT, Cambridge, Massachusetts 02142, United States
| | - Amedeo Vetere
- Center
for the Science of Therapeutics, Broad Institute of Harvard and MIT, Cambridge, Massachusetts 02142, United States
| | - Sarah Richardson
- University of Exeter Medical School, RD&E Hospital, Wonford EX2 5DW, U.K
| | - Noel G. Morgan
- University of Exeter Medical School, RD&E Hospital, Wonford EX2 5DW, U.K
| | - Dan Ploug Christensen
- Department
of Biomedical Sciences, University of Copenhagen, Copenhagen 1165, Denmark
| | - Tamara J. Gilbert
- Center
for the Science of Therapeutics, Broad Institute of Harvard and MIT, Cambridge, Massachusetts 02142, United States
| | - Jacob M. Hooker
- Stanley
Center for Psychiatric Research, Broad Institute of Harvard and MIT, Cambridge, Massachusetts 02142, United States
- Athinoula
A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital,
Department of Radiology, Harvard Medical School, Charlestown, Massachusetts 02129, United States
| | - Mélanie Leroy
- Stanley
Center for Psychiatric Research, Broad Institute of Harvard and MIT, Cambridge, Massachusetts 02142, United States
| | - Deepika Walpita
- Center
for the Science of Therapeutics, Broad Institute of Harvard and MIT, Cambridge, Massachusetts 02142, United States
| | - Thomas Mandrup-Poulsen
- Department
of Biomedical Sciences, University of Copenhagen, Copenhagen 1165, Denmark
- Department
of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm 171 77, Sweden
| | - Bridget K. Wagner
- Center
for the Science of Therapeutics, Broad Institute of Harvard and MIT, Cambridge, Massachusetts 02142, United States
| | - Edward B. Holson
- Stanley
Center for Psychiatric Research, Broad Institute of Harvard and MIT, Cambridge, Massachusetts 02142, United States
| |
Collapse
|
17
|
Walkup GK, You Z, Ross PL, Allen EKH, Daryaee F, Hale MR, O'Donnell J, Ehmann DE, Schuck VJA, Buurman ET, Choy AL, Hajec L, Murphy-Benenato K, Marone V, Patey SA, Grosser LA, Johnstone M, Walker SG, Tonge PJ, Fisher SL. Translating slow-binding inhibition kinetics into cellular and in vivo effects. Nat Chem Biol 2015; 11:416-23. [PMID: 25894085 DOI: 10.1038/nchembio.1796] [Citation(s) in RCA: 110] [Impact Index Per Article: 12.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2014] [Accepted: 03/19/2015] [Indexed: 01/18/2023]
Abstract
Many drug candidates fail in clinical trials owing to a lack of efficacy from limited target engagement or an insufficient therapeutic index. Minimizing off-target effects while retaining the desired pharmacodynamic (PD) response can be achieved by reduced exposure for drugs that display kinetic selectivity in which the drug-target complex has a longer half-life than off-target-drug complexes. However, though slow-binding inhibition kinetics are a key feature of many marketed drugs, prospective tools that integrate drug-target residence time into predictions of drug efficacy are lacking, hindering the integration of drug-target kinetics into the drug discovery cascade. Here we describe a mechanistic PD model that includes drug-target kinetic parameters, including the on- and off-rates for the formation and breakdown of the drug-target complex. We demonstrate the utility of this model by using it to predict dose response curves for inhibitors of the LpxC enzyme from Pseudomonas aeruginosa in an animal model of infection.
Collapse
Affiliation(s)
- Grant K Walkup
- Infection Innovative Medicines Unit, AstraZeneca Research and Development, Waltham, Massachusetts, USA
| | - Zhiping You
- Infection Innovative Medicines Unit, AstraZeneca Research and Development, Waltham, Massachusetts, USA
| | - Philip L Ross
- Infection Innovative Medicines Unit, AstraZeneca Research and Development, Waltham, Massachusetts, USA
| | - Eleanor K H Allen
- Institute for Chemical Biology and Drug Discovery, Department of Chemistry, Stony Brook University, Stony Brook, New York, USA
| | - Fereidoon Daryaee
- Institute for Chemical Biology and Drug Discovery, Department of Chemistry, Stony Brook University, Stony Brook, New York, USA
| | - Michael R Hale
- Infection Innovative Medicines Unit, AstraZeneca Research and Development, Waltham, Massachusetts, USA
| | - John O'Donnell
- Infection Innovative Medicines Unit, AstraZeneca Research and Development, Waltham, Massachusetts, USA
| | - David E Ehmann
- Infection Innovative Medicines Unit, AstraZeneca Research and Development, Waltham, Massachusetts, USA
| | - Virna J A Schuck
- Infection Innovative Medicines Unit, AstraZeneca Research and Development, Waltham, Massachusetts, USA
| | - Ed T Buurman
- Infection Innovative Medicines Unit, AstraZeneca Research and Development, Waltham, Massachusetts, USA
| | - Allison L Choy
- Infection Innovative Medicines Unit, AstraZeneca Research and Development, Waltham, Massachusetts, USA
| | - Laurel Hajec
- Infection Innovative Medicines Unit, AstraZeneca Research and Development, Waltham, Massachusetts, USA
| | - Kerry Murphy-Benenato
- Infection Innovative Medicines Unit, AstraZeneca Research and Development, Waltham, Massachusetts, USA
| | - Valerie Marone
- Infection Innovative Medicines Unit, AstraZeneca Research and Development, Waltham, Massachusetts, USA
| | - Sara A Patey
- Infection Innovative Medicines Unit, AstraZeneca Research and Development, Waltham, Massachusetts, USA
| | - Lena A Grosser
- Infection Innovative Medicines Unit, AstraZeneca Research and Development, Waltham, Massachusetts, USA
| | - Michele Johnstone
- Infection Innovative Medicines Unit, AstraZeneca Research and Development, Waltham, Massachusetts, USA
| | - Stephen G Walker
- Department of Oral Biology and Pathology, Stony Brook University, Stony Brook, New York, USA
| | - Peter J Tonge
- Institute for Chemical Biology and Drug Discovery, Department of Chemistry, Stony Brook University, Stony Brook, New York, USA
| | - Stewart L Fisher
- Infection Innovative Medicines Unit, AstraZeneca Research and Development, Waltham, Massachusetts, USA
| |
Collapse
|
18
|
Wagner FF, Zhang YL, Fass DM, Joseph N, Gale JP, Weïwer M, McCarren P, Fisher SL, Kaya T, Zhao WN, Reis SA, Hennig KM, Thomas M, Lemercier BC, Lewis MC, Guan JS, Moyer MP, Scolnick E, Haggarty SJ, Tsai LH, Holson EB. Kinetically Selective Inhibitors of Histone Deacetylase 2 (HDAC2) as Cognition Enhancers. Chem Sci 2015; 6:804-815. [PMID: 25642316 PMCID: PMC4310013 DOI: 10.1039/c4sc02130d] [Citation(s) in RCA: 74] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
Kinetically selective inhibitors of HDAC2 enhanced learning and memory in a CK-p25 mouse model of neurodegeneration.
Aiming towards the development of novel nootropic therapeutics to address the cognitive impairment common to a range of brain disorders, we set out to develop highly selective small molecule inhibitors of HDAC2, a chromatin modifying histone deacetylase implicated in memory formation and synaptic plasticity. Novel ortho-aminoanilide inhibitors were designed and evaluated for their ability to selectively inhibit HDAC2 versus the other Class I HDACs. Kinetic and thermodynamic binding properties were essential elements of our design strategy and two novel classes of ortho-aminoanilides, that exhibit kinetic selectivity (biased residence time) for HDAC2 versus the highly homologous isoform HDAC1, were identified. These kinetically selective HDAC2 inhibitors (BRD6688 and BRD4884) increased H4K12 and H3K9 histone acetylation in primary mouse neuronal cell culture assays, in the hippocampus of CK-p25 mice, a model of neurodegenerative disease, and rescued the associated memory deficits of these mice in a cognition behavioural model. These studies demonstrate for the first time that selective pharmacological inhibition of HDAC2 is feasible and that inhibition of the catalytic activity of this enzyme may serve as a therapeutic approach towards enhancing the learning and memory processes that are affected in many neurological and psychiatric disorders.
Collapse
Affiliation(s)
- F F Wagner
- Stanley Center for Psychiatric Research; Broad Institute of Harvard and MIT; 7 Cambridge Center, Cambridge, Massachusetts, USA
| | - Y-L Zhang
- Stanley Center for Psychiatric Research; Broad Institute of Harvard and MIT; 7 Cambridge Center, Cambridge, Massachusetts, USA
| | - D M Fass
- Stanley Center for Psychiatric Research; Broad Institute of Harvard and MIT; 7 Cambridge Center, Cambridge, Massachusetts, USA ; SL Fisher Consulting, LLC, PO Box 3052, Framingham, Massachusetts, USA
| | - N Joseph
- Stanley Center for Psychiatric Research; Broad Institute of Harvard and MIT; 7 Cambridge Center, Cambridge, Massachusetts, USA ; Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Howard Hughes Medical Institute, Cambridge, Massachusetts, USA
| | - J P Gale
- Stanley Center for Psychiatric Research; Broad Institute of Harvard and MIT; 7 Cambridge Center, Cambridge, Massachusetts, USA
| | - M Weïwer
- Stanley Center for Psychiatric Research; Broad Institute of Harvard and MIT; 7 Cambridge Center, Cambridge, Massachusetts, USA
| | - P McCarren
- Stanley Center for Psychiatric Research; Broad Institute of Harvard and MIT; 7 Cambridge Center, Cambridge, Massachusetts, USA
| | - S L Fisher
- SL Fisher Consulting, LLC, PO Box 3052, Framingham, Massachusetts, USA
| | - T Kaya
- Stanley Center for Psychiatric Research; Broad Institute of Harvard and MIT; 7 Cambridge Center, Cambridge, Massachusetts, USA
| | - W-N Zhao
- Stanley Center for Psychiatric Research; Broad Institute of Harvard and MIT; 7 Cambridge Center, Cambridge, Massachusetts, USA ; Chemical Neurobiology Laboratory, Center for Human Genetic Research, Massachusetts General Hospital, Department of Neurology and Psychiatry, Harvard Medical School, Boston, Massachusetts, USA
| | - S A Reis
- Stanley Center for Psychiatric Research; Broad Institute of Harvard and MIT; 7 Cambridge Center, Cambridge, Massachusetts, USA ; Chemical Neurobiology Laboratory, Center for Human Genetic Research, Massachusetts General Hospital, Department of Neurology and Psychiatry, Harvard Medical School, Boston, Massachusetts, USA
| | - K M Hennig
- Stanley Center for Psychiatric Research; Broad Institute of Harvard and MIT; 7 Cambridge Center, Cambridge, Massachusetts, USA ; Chemical Neurobiology Laboratory, Center for Human Genetic Research, Massachusetts General Hospital, Department of Neurology and Psychiatry, Harvard Medical School, Boston, Massachusetts, USA
| | - M Thomas
- Stanley Center for Psychiatric Research; Broad Institute of Harvard and MIT; 7 Cambridge Center, Cambridge, Massachusetts, USA
| | - B C Lemercier
- Stanley Center for Psychiatric Research; Broad Institute of Harvard and MIT; 7 Cambridge Center, Cambridge, Massachusetts, USA
| | - M C Lewis
- Stanley Center for Psychiatric Research; Broad Institute of Harvard and MIT; 7 Cambridge Center, Cambridge, Massachusetts, USA
| | - J S Guan
- Stanley Center for Psychiatric Research; Broad Institute of Harvard and MIT; 7 Cambridge Center, Cambridge, Massachusetts, USA ; Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Howard Hughes Medical Institute, Cambridge, Massachusetts, USA
| | - M P Moyer
- Stanley Center for Psychiatric Research; Broad Institute of Harvard and MIT; 7 Cambridge Center, Cambridge, Massachusetts, USA
| | - E Scolnick
- Stanley Center for Psychiatric Research; Broad Institute of Harvard and MIT; 7 Cambridge Center, Cambridge, Massachusetts, USA
| | - S J Haggarty
- Stanley Center for Psychiatric Research; Broad Institute of Harvard and MIT; 7 Cambridge Center, Cambridge, Massachusetts, USA ; Chemical Neurobiology Laboratory, Center for Human Genetic Research, Massachusetts General Hospital, Department of Neurology and Psychiatry, Harvard Medical School, Boston, Massachusetts, USA
| | - L-H Tsai
- Stanley Center for Psychiatric Research; Broad Institute of Harvard and MIT; 7 Cambridge Center, Cambridge, Massachusetts, USA ; Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Howard Hughes Medical Institute, Cambridge, Massachusetts, USA
| | - E B Holson
- Stanley Center for Psychiatric Research; Broad Institute of Harvard and MIT; 7 Cambridge Center, Cambridge, Massachusetts, USA
| |
Collapse
|
19
|
Ehmann DE, Jahic H, Ross PL, Gu RF, Hu J, Durand-Réville TF, Lahiri S, Thresher J, Livchak S, Gao N, Palmer T, Walkup GK, Fisher SL. Kinetics of avibactam inhibition against Class A, C, and D β-lactamases. J Biol Chem 2013; 288:27960-71. [PMID: 23913691 DOI: 10.1074/jbc.m113.485979] [Citation(s) in RCA: 270] [Impact Index Per Article: 24.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Avibactam is a non-β-lactam β-lactamase inhibitor with a spectrum of activity that includes β-lactamase enzymes of classes A, C, and selected D examples. In this work acylation and deacylation rates were measured against the clinically important enzymes CTX-M-15, KPC-2, Enterobacter cloacae AmpC, Pseudomonas aeruginosa AmpC, OXA-10, and OXA-48. The efficiency of acylation (k2/Ki) varied across the enzyme spectrum, from 1.1 × 10(1) m(-1)s(-1) for OXA-10 to 1.0 × 10(5) for CTX-M-15. Inhibition of OXA-10 was shown to follow the covalent reversible mechanism, and the acylated OXA-10 displayed the longest residence time for deacylation, with a half-life of greater than 5 days. Across multiple enzymes, acyl enzyme stability was assessed by mass spectrometry. These inhibited enzyme forms were stable to rearrangement or hydrolysis, with the exception of KPC-2. KPC-2 displayed a slow hydrolytic route that involved fragmentation of the acyl-avibactam complex. The identity of released degradation products was investigated, and a possible mechanism for the slow deacylation from KPC-2 is proposed.
Collapse
Affiliation(s)
- David E Ehmann
- From the Infection Innovative Medicines Unit and the Discovery Sciences Innovative Medicines Unit, AstraZeneca R&D Boston, Waltham, Massachusetts 02451
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Reck F, Alm RA, Brassil P, Newman JV, Ciaccio P, McNulty J, Barthlow H, Goteti K, Breen J, Comita-Prevoir J, Cronin M, Ehmann DE, Geng B, Godfrey AA, Fisher SL. Novel N-Linked Aminopiperidine Inhibitors of Bacterial Topoisomerase Type II with Reduced pKa: Antibacterial Agents with an Improved Safety Profile. J Med Chem 2012; 55:6916-33. [DOI: 10.1021/jm300690s] [Citation(s) in RCA: 73] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | | | | | - Andrew Aydon Godfrey
- Pharmaceutical
Development, Chemical Sciences, AstraZeneca, Silk Road Business Park, Macclesfield, SK10 4TG Cheshire, England
| | | |
Collapse
|
21
|
Ehmann DE, Jahić H, Ross PL, Gu RF, Hu J, Kern G, Walkup GK, Fisher SL. Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor. Proc Natl Acad Sci U S A 2012; 109:11663-8. [PMID: 22753474 PMCID: PMC3406822 DOI: 10.1073/pnas.1205073109] [Citation(s) in RCA: 369] [Impact Index Per Article: 30.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Avibactam is a β-lactamase inhibitor that is in clinical development, combined with β-lactam partners, for the treatment of bacterial infections comprising gram-negative organisms. Avibactam is a structural class of inhibitor that does not contain a β-lactam core but maintains the capacity to covalently acylate its β-lactamase targets. Using the TEM-1 enzyme, we characterized avibactam inhibition by measuring the on-rate for acylation and the off-rate for deacylation. The deacylation off-rate was 0.045 min(-1), which allowed investigation of the deacylation route from TEM-1. Using NMR and MS, we showed that deacylation proceeds through regeneration of intact avibactam and not hydrolysis. Other than TEM-1, four additional clinically relevant β-lactamases were shown to release intact avibactam after being acylated. We showed that avibactam is a covalent, slowly reversible inhibitor, which is a unique mechanism of inhibition among β-lactamase inhibitors.
Collapse
Affiliation(s)
- David E Ehmann
- Infection Innovative Medicines Unit, AstraZeneca Research & Development Boston, Waltham, MA 02451, USA.
| | | | | | | | | | | | | | | |
Collapse
|
22
|
Abstract
The bacterial cell wall is a highly cross-linked polymeric structure consisting of repeating peptidoglycan units, each of which contains a novel pentapeptide substitution which is cross-linked through transpeptidation. The incorporation of D-glutamate as the second residue is strictly conserved across the bacterial kingdom. Glutamate racemase, a member of the cofactor-independent, two-thiol-based family of amino acid racemases, has been implicated in the production and maintenance of sufficient d-glutamate pool levels required for growth. The subject of over four decades of research, it is now evident that the enzyme is conserved and essential for growth across the bacterial kingdom and has a conserved overall topology and active site architecture; however, several different mechanisms of regulation have been observed. These traits have recently been targeted in the discovery of both narrow and broad spectrum inhibitors. This review outlines the biological history of this enzyme, the recent biochemical and structural characterization of isozymes from a wide range of species and developments in the identification of inhibitors that target the enzyme as possible therapeutic agents.
Collapse
Affiliation(s)
- Stewart L Fisher
- Infection Discovery, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, MA 02451, USA.
| |
Collapse
|
23
|
Lundqvist T, Fisher SL, Kern G, Folmer RHA, Xue Y, Newton DT, Keating TA, Alm RA, de Jonge BLM. Exploitation of structural and regulatory diversity in glutamate racemases. Nature 2007; 447:817-22. [PMID: 17568739 DOI: 10.1038/nature05689] [Citation(s) in RCA: 111] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2006] [Accepted: 02/14/2007] [Indexed: 11/09/2022]
Abstract
Glutamate racemase is an enzyme essential to the bacterial cell wall biosynthesis pathway, and has therefore been considered as a target for antibacterial drug discovery. We characterized the glutamate racemases of several pathogenic bacteria using structural and biochemical approaches. Here we describe three distinct mechanisms of regulation for the family of glutamate racemases: allosteric activation by metabolic precursors, kinetic regulation through substrate inhibition, and D-glutamate recycling using a d-amino acid transaminase. In a search for selective inhibitors, we identified a series of uncompetitive inhibitors specifically targeting Helicobacter pylori glutamate racemase that bind to a cryptic allosteric site, and used these inhibitors to probe the mechanistic and dynamic features of the enzyme. These structural, kinetic and mutational studies provide insight into the physiological regulation of these essential enzymes and provide a basis for designing narrow-spectrum antimicrobial agents.
Collapse
Affiliation(s)
- Tomas Lundqvist
- AstraZeneca Global Structural Chemistry, AstraZeneca R&D Mölndal, SE-431 83, Mölndal, Sweden
| | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Ehmann DE, Demeritt JE, Hull KG, Fisher SL. Biochemical characterization of an inhibitor of Escherichia coli UDP-N-acetylmuramyl-l-alanine ligase. Biochim Biophys Acta 2004; 1698:167-74. [PMID: 15134649 DOI: 10.1016/j.bbapap.2003.11.006] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/29/2003] [Accepted: 11/07/2003] [Indexed: 11/24/2022]
Abstract
UDP-N-acetylmuramyl-l-alanine ligase (MurC) is an essential bacterial enzyme involved in peptidoglycan biosynthesis and a target for the discovery of novel antibacterial agents. As a result of a high-throughput screen (HTS) against a chemical library for inhibitors of MurC, a series of benzofuran acyl-sulfonamides was identified as potential leads. One of these compounds, Compound A, inhibited Escherichia coli MurC with an IC(50) of 2.3 microM. Compound A exhibited time-dependent, partially reversible inhibition of E. coli MurC. Kinetic studies revealed a mode of inhibition consistent with the compound acting competitively with the MurC substrates ATP and UDP-N-acetyl-muramic acid (UNAM) with a K(i) of 4.5 microM against ATP and 6.3 microM against UNAM. Fluorescence binding experiments yielded a K(d) of 3.1 microM for the compound binding to MurC. Compound A also exhibited high-affinity binding to bovine serum albumin (BSA) as evidenced by a severe reduction in MurC inhibition upon addition of BSA. This finding is consistent with the high lipophilicity of the compound. Advancement of this compound series for further drug development will require reduction of albumin binding.
Collapse
Affiliation(s)
- David E Ehmann
- Department of Biochemistry, Infection Discovery, Cancer and Infection Research Area, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, MA 02451, USA.
| | | | | | | |
Collapse
|
25
|
Deng G, Gu RF, Marmor S, Fisher SL, Jahic H, Sanyal G. Development of an LC–MS based enzyme activity assay for MurC: application to evaluation of inhibitors and kinetic analysis. J Pharm Biomed Anal 2004; 35:817-28. [PMID: 15193726 DOI: 10.1016/j.jpba.2004.02.029] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2003] [Revised: 02/06/2004] [Accepted: 02/07/2004] [Indexed: 11/15/2022]
Abstract
An enzyme activity assay, based on mass spectrometric (MS) detection of specific reaction product following HPLC separation, has been developed to evaluate pharmaceutical hits identified from primary high throughput screening (HTS) against target enzyme Escherichia coli UDP-N-acetyl-muramyl-L-alanine ligase (MurC), an essential enzyme in the bacterial peptidoglycan biosynthetic pathway, and to study the kinetics of the enzyme. A comparative analysis of this new liquid chromatographic-MS (LC-MS) based assay with a conventional spectrophotometric Malachite Green (MG) assay, which detects phosphate produced in the reaction, was performed. The results demonstrated that the LC-MS assay, which determines specific ligase activity of MurC, offers several advantages including a lower background (0.2% versus 26%), higher sensitivity (> or = 10 fold), lower limit of quantitation (LOQ) (0.02 microM versus 1 microM) and wider linear dynamic range (> or = 4 fold) than the MG assay. Good precision for the LC-MS assay was demonstrated by the low intraday and interday coefficient of variation (CV) values (3 and 6%, respectively). The LC-MS assay, free of the artifacts often seen in the Malachite Green assay, offers a valuable secondary assay for hit evaluation in which the false positives from the primary high throughput screening can be eliminated. In addition, the applicability of this assay to the study of enzyme kinetics has also been demonstrated.
Collapse
Affiliation(s)
- Gejing Deng
- Infection Discovery, Department of Biochemistry, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, MA 02451, USA.
| | | | | | | | | | | |
Collapse
|
26
|
|
27
|
Imperiali B, Fisher SL. (S)-.alpha.-Amino-(2,2'-bipyridine)-6-propanoic acid: a versatile amino acid for de novo metalloprotein design. J Am Chem Soc 2002. [DOI: 10.1021/ja00022a053] [Citation(s) in RCA: 42] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
28
|
Wuttke DS, Gray HB, Fisher SL, Imperiali B. Semisynthesis of bipyridyl-alanine cytochrome c mutants: novel proteins with enhanced electron-transfer properties. J Am Chem Soc 2002. [DOI: 10.1021/ja00071a068] [Citation(s) in RCA: 41] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
29
|
Imperiali B, Fisher SL. Stereoselective synthesis and peptide incorporation of (S)-.alpha.-amino-(2,2'-bipyridine)-6-propanoic acid. J Org Chem 2002. [DOI: 10.1021/jo00028a068] [Citation(s) in RCA: 57] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
30
|
Abstract
The bacterial UDP-N-acetylmuramyl-L-alanine ligase (MurC) from Escherichia coli, an essential, cytoplasmic peptidoglycan biosynthetic enzyme, catalyzes the ATP-dependent ligation of L-alanine (Ala) and UDP-N-acetylmuramic acid (UNAM) to form UDP-N-acetylmuramyl-L-alanine (UNAM-Ala). The phosphinate inhibitor 1 was designed and prepared as a multisubstrate/transition state analogue. The compound exhibits mixed-type inhibition with respect to all three enzyme substrates (ATP, UNAM, Ala), suggesting that this compound forms dead-end complexes with multiple enzyme states. Results from isothermal titration calorimetry (ITC) studies supported these findings as exothermic binding was observed under conditions with free enzyme (K(d) = 1.80-2.79 microM, 95% CI), enzyme saturated with ATP (K(d) = 0.097-0.108 microM, 95% CI), and enzyme saturated with the reaction product ADP (K(d) = 0.371-0.751 microM, 95% CI). Titrations run under conditions of saturating UNAM or the product UNAM-Ala did not show heat effects consistent with competitive compound binding to the active site. The potent binding affinity observed in the presence of ATP is consistent with the inhibitor design and the proposed Ordered Ter-Ter mechanism for this enzyme; however, the additional binding pathways suggest that the inhibitor can also serve as a product analogue.
Collapse
Affiliation(s)
- S Marmor
- Department of Biochemistry, Cancer and Infection Research Area, AstraZeneca R&D Boston, Waltham, Massachusetts 02451, USA
| | | | | | | | | | | |
Collapse
|
31
|
Gu W, Tu Z, Kleyn PW, Kissebah A, Duprat L, Lee J, Chin W, Maruti S, Deng N, Fisher SL, Franco LS, Burn P, Yagaloff KA, Nathan J, Heymsfield S, Albu J, Pi-Sunyer FX, Allison DB. Identification and functional analysis of novel human melanocortin-4 receptor variants. Diabetes 1999; 48:635-9. [PMID: 10078568 DOI: 10.2337/diabetes.48.3.635] [Citation(s) in RCA: 141] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Inactivation of the melanocortin-4 receptor (MC4-R) by gene-targeting results in mice that develop maturity-onset obesity, hyperinsulinemia, and hyperglycemia. These phenotypes resemble common forms of human obesity, which are late-onset and frequently accompanied by NIDDM. It is not clear whether sequence variation of the MC4-R gene contributes to obesity in humans. Therefore, we examined the human MC4-R gene polymorphism in 190 individuals ascertained on obesity status. Three allelic variants were identified, including two novel ones, Thr112Met and Ile137Thr. To analyze possible functional alterations, the variants were cloned and expressed in vitro and compared with the wild-type receptor. One of the novel variants, Ile137Thr, identified in an extremely obese proband (BMI 57), was found to be severely impaired in ligand binding and signaling, raising the possibility that it may contribute to development of obesity. Furthermore, our results also suggest that sequence polymorphism in the MC4-R coding region is unlikely to be a common cause of obesity in the population studied, given the low frequency of functionally significant mutations.
Collapse
Affiliation(s)
- W Gu
- Millennium Pharmaceuticals, Cambridge, Massachusetts 02139, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Abstract
For many years, genetically obese mouse strains have provided models for human obesity. The Avy/-agouti mouse, one of the oldest obese mouse models, is characterized by maturity-onset obesity and diabetes as a result of ectopic expression of the secreted protein hormone, agouti protein. Agouti protein is normally expressed in hair follicles to regulate pigmentation through antagonism of the melanocortin-1 receptor, but in-vitro studies have demonstrated that the hormone also has potent antagonist activity for the melanocortin-4 receptor (MC4-R). Subsequent development of the MC4-R knockout mouse model demonstrated that MC4-R plays a role in weight homeostasis as these mice recapitulated the metabolic defects of the agouti mouse. Further evidence for this hypothesis was obtained from pharmacological studies utilizing peptides with MC4-R agonist activity, that inhibited food intake (when administered intracerebrally). Additional studies with peptide antagonists have now implicated the MC4-R in the leptin signalling pathway. Finally, evidence that the MC4-R may play a role in human obesity has been obtained from the identification of a dis-functional variant of the receptor in genetically obese subjects.
Collapse
Affiliation(s)
- S L Fisher
- Department of Metabolic Diseases, Hoffmann LaRoche, Nutley, NJ 07110, USA
| | | | | |
Collapse
|
33
|
Marsh DJ, Hollopeter G, Huszar D, Laufer R, Yagaloff KA, Fisher SL, Burn P, Palmiter RD. Response of melanocortin-4 receptor-deficient mice to anorectic and orexigenic peptides. Nat Genet 1999; 21:119-22. [PMID: 9916804 DOI: 10.1038/5070] [Citation(s) in RCA: 437] [Impact Index Per Article: 17.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Mutations reducing the functional activity of leptin, the leptin receptor, alpha-melanocyte stimulating hormones (alpha-MSH) and the melanocortin-4 receptor (Mc4r) all lead to obesity in mammals. Moreover, mutant mice that ectopically express either agouti (Ay/a mice) or agouti-related protein (Agrp), antagonists of melanocortin signalling, become obese. These data suggest that alpha-MSH signalling transduced by Mc4r tonically inhibits feeding; however, it is not known to what extent this pathway mediates leptin signalling. We show here that Mc4r-deficient (Mc4r-/-) mice do not respond to the anorectic actions of MTII, an MSH-like agonist, suggesting that alpha-MSH inhibits feeding primarily by activating Mc4r. Obese Mc4r-/-mice do not respond significantly to the inhibitory effects of leptin on feeding, whereas non-obese Mc4r-/- mice do. These data demonstrate that melanocortin signalling transduced by Mc4r is not an exclusive target of leptin action and that factors resulting from obesity contribute to leptin resistance. Leptin resistance of obese Mc4r-/- mice does not prevent their response to the anorectic actions of ciliary neurotrophic factor (CNTF), corticotropin releasing factor (CRF), or urocortin; or the orexigenic actions of neuropeptide Y (NPY) or peptide YY (PYY), indicating that these neuromodulators act independently or downstream of Mc4r signalling.
Collapse
Affiliation(s)
- D J Marsh
- Howard Hughes Medical Institute and Department of Biochemistry, University of Washington, Seattle 98195, USA
| | | | | | | | | | | | | | | |
Collapse
|
34
|
Abstract
The recent cloning of the ob gene (leptin) has revolutionized our understanding of obesity and the underlying factors that govern weight homeostasis. There is growing evidence that long term food intake regulation is controlled by the central nervous system by a number of peptide hormones in response to changes in leptin levels. Studies of these hormones, using both genetic and pharmacological approaches, have provided a foundation for decoding the molecular logic of the neuronal circuits which regulate food intake control and energy balance. A review of the current progress in the melanocortin-4 receptor pathway, with particular emphasis on its relation to leptin, neuropeptide Y and other obesity hormones known to modulate weight homeostasis, is presented.
Collapse
Affiliation(s)
- S L Fisher
- Department of Metabolic Diseases, Hoffmann LaRoche, Inc., Nutley, NJ 07110, USA
| | | | | |
Collapse
|
35
|
Zeng W, Xu X, Popov S, Mukhopadhyay S, Chidiac P, Swistok J, Danho W, Yagaloff KA, Fisher SL, Ross EM, Muallem S, Wilkie TM. The N-terminal domain of RGS4 confers receptor-selective inhibition of G protein signaling. J Biol Chem 1998; 273:34687-90. [PMID: 9856989 DOI: 10.1074/jbc.273.52.34687] [Citation(s) in RCA: 206] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Regulators of heterotrimeric G protein signaling (RGS) proteins are GTPase-activating proteins (GAPs) that accelerate GTP hydrolysis by Gq and Gi alpha subunits, thus attenuating signaling. Mechanisms that provide more precise regulatory specificity have been elusive. We report here that an N-terminal domain of RGS4 discriminated among receptor signaling complexes coupled via Gq. Accordingly, deletion of the N-terminal domain of RGS4 eliminated receptor selectivity and reduced potency by 10(4)-fold. Receptor selectivity and potency of inhibition were partially restored when the RGS4 box was added together with an N-terminal peptide. In vitro reconstitution experiments also indicated that sequences flanking the RGS4 box were essential for high potency GAP activity. Thus, RGS4 regulates Gq class signaling by the combined action of two domains: 1) the RGS box accelerates GTP hydrolysis by Galphaq and 2) the N terminus conveys high affinity and receptor-selective inhibition. These activities are each required for receptor selectivity and high potency inhibition of receptor-coupled Gq signaling.
Collapse
Affiliation(s)
- W Zeng
- Department of Physiology, University of Texas Southwestern Medical Center, Dallas, Texas 75235, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Thiele TE, van Dijk G, Yagaloff KA, Fisher SL, Schwartz M, Burn P, Seeley RJ. Central infusion of melanocortin agonist MTII in rats: assessment of c-Fos expression and taste aversion. Am J Physiol 1998; 274:R248-54. [PMID: 9458925 DOI: 10.1152/ajpregu.1998.274.1.r248] [Citation(s) in RCA: 61] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Like leptin (OB protein), central infusion of the nonspecific melanocortin agonist MTII reduces food intake for relatively long periods of time (i.e., 12 h; W. Fan, B. A. Boston, R. A. Kesterson, V. J. Hruby, and R. D. Cone, Nature; 385: 165-168, 1997). To test the hypothesis that MTII may influence ingestive behavior via mechanisms similar to those that mediate the effects of leptin, we infused a single dose of MTII into the third ventricle (i3vt) of Long-Evans rats and examined three dependent measures that have been studied following i3vt infusion of leptin: 1) effects on long-term food intake and body weight (48 h), 2) patterns of c-Fos expression in the brain, and 3) conditioned taste aversion learning. Similar to leptin, MTII reduced 48-h food intake (1.0 nmol dose), reduced body weight at 24 and 48 h (0.1 and 1.0 nmol doses, respectively), and induced c-Fos expression in the paraventricular nucleus of the hypothalamus and the central nucleus of the amygdala. In contrast to leptin, MTII was found to produce conditioned taste aversions. These results are consistent with the hypothesis that MTII may influence regulatory behavior via mechanisms similar to those that mediate the effects of leptin.
Collapse
Affiliation(s)
- T E Thiele
- Department of Psychology, University of Washington, Seattle 98195, USA
| | | | | | | | | | | | | |
Collapse
|
37
|
Seeley RJ, Yagaloff KA, Fisher SL, Burn P, Thiele TE, van Dijk G, Baskin DG, Schwartz MW. Melanocortin receptors in leptin effects. Nature 1997; 390:349. [PMID: 9389472 DOI: 10.1038/37016] [Citation(s) in RCA: 406] [Impact Index Per Article: 15.0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
|
38
|
Haldimann A, Fisher SL, Daniels LL, Walsh CT, Wanner BL. Transcriptional regulation of the Enterococcus faecium BM4147 vancomycin resistance gene cluster by the VanS-VanR two-component regulatory system in Escherichia coli K-12. J Bacteriol 1997; 179:5903-13. [PMID: 9294451 PMCID: PMC179483 DOI: 10.1128/jb.179.18.5903-5913.1997] [Citation(s) in RCA: 52] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
An Escherichia coli K-12 model system was developed for studying the VanS-VanR two-component regulatory system required for high-level inducible vancomycin resistance in Enterococcus faecium BM4147. Our model system is based on the use of reporter strains with lacZ transcriptional and translational fusions to the PvanR or PvanH promoter of the vanRSHAX gene cluster. These strains also express vanR and vanS behind the native PvanR promoter, the arabinose-inducible ParaB promoter, or the rhamnose-inducible PrhaB promoter. Our reporter strains have the respective fusions stably recombined onto the chromosome in single copy, thereby avoiding aberrant regulatory effects that may occur with plasmid-bearing strains. They were constructed by using allele replacement methods or a conditionally replicative attP plasmid. Using these reporter strains, we demonstrated that (i) the response regulator VanR activates PvanH, but not PvanR, expression upon activation (phosphorylation) by the partner kinase VanS, the noncognate kinase PhoR, or acetyl phosphate, indicating that phospho-VanR (P-VanR) is a transcriptional activator; (ii) VanS interferes with activation of VanR by PhoR or acetyl phosphate, indicating that VanS also acts as a P-VanR phosphatase; and (iii) the conserved, phosphate-accepting histidine (H164) of VanS is required for activation (phosphorylation) of VanR but not for deactivation (dephosphorylation) of P-VanR. Similar reporter strains may be useful in new studies on these and other interactions of the VanS-VanR system (and other systems), screening for inhibitors of these interactions, and deciphering the molecular logic of the signal(s) responsible for activation of the VanS-VanR system in vivo. Advantages of using an E. coli model system for in vivo studies on VanS and VanR are also discussed.
Collapse
Affiliation(s)
- A Haldimann
- Department of Biological Sciences, Purdue University, West Lafayette, Indiana 47907, USA
| | | | | | | | | |
Collapse
|
39
|
Haldimann A, Prahalad MK, Fisher SL, Kim SK, Walsh CT, Wanner BL. Altered recognition mutants of the response regulator PhoB: a new genetic strategy for studying protein-protein interactions. Proc Natl Acad Sci U S A 1996; 93:14361-6. [PMID: 8962056 PMCID: PMC26137 DOI: 10.1073/pnas.93.25.14361] [Citation(s) in RCA: 53] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023] Open
Abstract
Two-component regulatory systems require highly specific interactions between histidine kinase (transmitter) and response regulator (receiver) proteins. We have developed a novel genetic strategy that is based on tightly regulated synthesis of a given protein to identify domains and residues of an interacting protein that are critical for interactions between them. Using a reporter strain synthesizing the nonpartner kinase VanS under tight arabinose control and carrying a promoter-lacZ fusion activated by phospho-PhoB, we isolated altered recognition (AR) mutants of PhoB showing enhanced activation (phosphorylation) by VanS as arabinose-dependent Lac+ mutants. Changes in the PhoBAR mutants cluster in a "patch" near the proposed helix 4 of PhoB based on the CheY crystal structure (a homolog of the PhoB receiver domain) providing further evidence that helix 4 lies in the kinase-regulator interface. Based on the CheY structure, one mutant has an additional change in a region that may propagate a conformational change to helix 4. The overall genetic strategy described here may also be useful for studying interactions of other components of the vancomycin resistance and P1 signal transduction pathways, other two-component regulatory systems, and other interacting proteins. Conditionally replicative oriRR6K gamma attP "genome targeting" suicide plasmids carrying mutagenized phoB coding regions were integrated into the chromosome of a reporter strain to create mutant libraries; plasmids encoding mutant PhoB proteins were subsequently retrieved by P1-Int-Xis cloning. Finally, the use of similar genome targeting plasmids and P1-Int-Xis cloning should be generally useful for constructing genomic libraries from a wide array of organisms.
Collapse
Affiliation(s)
- A Haldimann
- Department of Biological Sciences, Purdue University, West Lafayette, IN 47907, USA
| | | | | | | | | | | |
Collapse
|
40
|
Cheng RP, Fisher SL, Imperiali B. Metallopeptide Design: Tuning the Metal Cation Affinities with Unnatural Amino Acids and Peptide Secondary Structure. J Am Chem Soc 1996. [DOI: 10.1021/ja9619723] [Citation(s) in RCA: 78] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Richard P. Cheng
- Division of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, California 91125
| | - Stewart L. Fisher
- Division of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, California 91125
| | - Barbara Imperiali
- Division of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, California 91125
| |
Collapse
|
41
|
Fisher SL, Kim SK, Wanner BL, Walsh CT. Kinetic comparison of the specificity of the vancomycin resistance VanSfor two response regulators, VanR and PhoB. Biochemistry 1996; 35:4732-40. [PMID: 8664263 DOI: 10.1021/bi9525435] [Citation(s) in RCA: 63] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
Induction of vancomycin resistance in the Gram-positive Enterococci requires a two-componet regulatory system, VanS and VanR, for transcriptional activation of three genes (vanH, A, X) that encode enzymes for a cell wall biosynthetic pathway that produces an altered peptidoglycan intermediate with lower affinity for the antibiotic. The catalytic efficiency (kcat/KM) has been determined for phosphotransfer from the phosphohistidyl form of VanS to both its homologous partner VanR and the heterologous (Escherichia coli) response regulator Phob. The rate of formation of the phosphoaapartyl forms of VanR and PhoB were determined as well as the rate of appearance of inorganic phosphate. Using PhoB in excess of P-VanS, a pseudo-first-order rate constant (kxfer) of 0.2 min-1 for phosphotransfer and a KM for PhoB of 100 microM were readily determined. The corresponding kxfer of 96 min-1 for phosphotransfer from P-VanS to VanR required quench kinetics. A KM of 3 microM was estimated for VanR, leading to a 10(4)-fold preference in kxfer/KM for phosphotransfer to VanR compared to PhoB. No phosphotransfer was detachable to three other E. coli response regulators, OmpR, ArcB, or CreB, providing some sense of the selectivity against two-component regulatory system cross-talk. In the phosphotransfer from P-VanS to PhoB and VanR, there was evidence of competition between water, to give Pi, and the specific aspartyl beta-COO- moiety of either PhoB or VanR with about 25% of the initial flux generating inorganic phosphate. The kinetics of phosphotransfer from P-VanS to VanR were complicated by inhibition by free VanS but, the inhibition pattern could be modeled to yield at KD of 30 nM for VanR binding to free VanS, an affinity similar to that of the CheA-CheY pair in E. coli chemotaxis.
Collapse
Affiliation(s)
- S L Fisher
- Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02115, USA
| | | | | | | |
Collapse
|
42
|
Abstract
A plasmid-borne transposon encodes enzymes and regulator proteins that confer resistance of enterococcal bacteria to the antibiotic vancomycin. Purification and characterization of individual proteins encoded by this operon has helped to elucidate the molecular basis of vancomycin resistance. This new understanding provides opportunities for intervention to reverse resistance.
Collapse
Affiliation(s)
- C T Walsh
- Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA
| | | | | | | | | |
Collapse
|
43
|
Fisher SL, Jiang W, Wanner BL, Walsh CT. Cross-talk between the histidine protein kinase VanS and the response regulator PhoB. Characterization and identification of a VanS domain that inhibits activation of PhoB. J Biol Chem 1995; 270:23143-9. [PMID: 7559459 DOI: 10.1074/jbc.270.39.23143] [Citation(s) in RCA: 66] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023] Open
Abstract
VanS is a two-component transmembrane sensory kinase that, together with its response regulator VanR, activates the expression of genes responsible for vancomycin resistance in Enterococcus faecium BM4147. In this report, we demonstrate that the cytoplasmic domain of VanS (including residues Met95 to Ser384) is capable of high level activation (> 500 fold) of the Escherichia coli response regulator PhoB in vivo in the absence of its signaling kinases PhoR, CreC (PhoM), or acetyl phosphate synthesis. In vitro experiments carried out on the purified proteins confirmed that the activation is due to efficient cross-talk between VanS and PhoB, since phospho-VanS catalyzed transfer of its phosphoryl group to PhoB with approximately 90% transfer in 5 min at a 1:4 VanS/PhoB stoichiometry. However, the rate of transfer was at least 100-fold slower than that observed between phospho-VanS and VanR. The in vivo activation of PhoB was used as a reporter system to identify peptide fragments of VanS capable of interfering with activation by VanS(Met95-Ser384), in order to identify an interaction domain. A library of plasmids encoding fragments of VanS(Met95-Ser384) was constructed using transposon mutagenesis, and a subpopulation of these plasmids encoded peptides that interfered with activation of PhoB by VanS(Met95-Ser384). A minimal size fragment (Met95-Ile174) was shown to be both necessary and sufficient for potent inhibition (85%) of this activation.
Collapse
Affiliation(s)
- S L Fisher
- Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02115, USA
| | | | | | | |
Collapse
|
44
|
Wuttke DS, Gray HB, Fisher SL, Imperial B. Semisynthesis of bipyridyl-alanine cytochrome c mutants: Novel protein structures with enhanced electron-transfer properties. J Inorg Biochem 1993. [DOI: 10.1016/0162-0134(93)85269-e] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
45
|
Affiliation(s)
- S L Fisher
- Department of Surgery, Fresno Calif, Community Hospital and Medical Center
| |
Collapse
|
46
|
Abstract
First phase insulin release was measured in response to intravenous glucose given weekly from approximately day 40 in 6 BB rats which subsequently developed diabetes and in age-matched non-diabetic (n = 15) and normal Wistar rats (n = 8) until day 180. The mean sequential insulin responses in BB rats with and without diabetes were significantly lower (p = 0.008 and less than 0.0001, respectively) than in normal rats from an early age. Five diabetic BB rats showed a progressive decline in first phase insulin release immediately prior to glycosuria, with the impaired phases ranging from 25-50 days. However, protracted periods of low first phase responses were also seen in several aglycosuric BB rats, which showed histological evidence of insulitis and B-cell loss. Our findings demonstrate that, although most BB rats with diabetes show a progressive impairment of B-cell function preceding the disease, this aberrant phase can also be present in BB rats which remain aglycosuric. Impaired first phase insulin release in response to serial intravenous glucose tolerance tests may not be a reliable predictor of Type 1 (insulin-dependent) diabetes in this animal model.
Collapse
|
47
|
Reddy S, Bibby NJ, Fisher SL, Elliott RB. Immunolocalization of insulin, glucagon, pancreatic polypeptide, and somatostatin in the pancreatic islets of the possum, Trichosurus vulpecula. Gen Comp Endocrinol 1986; 64:157-62. [PMID: 2881838 DOI: 10.1016/0016-6480(86)90042-0] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Antibodies to insulin, glucagon, pancreatic polypeptide (PP), and somatostatin were used in the immunofluorescence procedure to demonstrate localization of the four hormones in cells of the pancreatic islets of the brushtailed possum, Trichosurus vulpecula. Most pancreatic islets revealed some differences in the topographical distribution and cell number of each endocrine cell type. Insulin immunoreactive cells were observed in most islets where they occurred as groups of cells peripherally and within the islet. In several islets glucagon cells were the predominant cell population and were distributed peripherally as well as centrally. Pancreatic polypeptide cells were fewer in number and usually occurred as single cells within the islet. Cells immunoreactive to antisomatostatin serum were observed in varying numbers in the peripheral and central regions of the islet. The present immunofluorescence study demonstrates differences in the topographical distribution of the four major pancreatic hormones between a marsupial species and several of the eutherian mammals.
Collapse
|
48
|
Tolkoff-Rubin NE, Fisher SL, O'Brien JT, Rubin RH. Coordinated home care: the Massachusetts General Hospital experience. Med Care 1978; 16:453-64. [PMID: 651408] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
The problem of post-hospital care remains a continued challenge, as many patients who no longer require expensive acute care facilities continue to occupy these beds, awaiting appropriate placement. The Massachusetts General Hospital Coordinated Home Care program, under the central administration of the Boston Visiting Nurse Association, has demonstrated that home care can be a viable, economically feasible alternative to institutionalization for carefully selected patients, when the appropriate medical and social needs can be met. Three major groups of patients have been effectively cared for: 1) patients with multi-system chronic illness; 2) patients with terminal malignancies; and 3) patients with catastrophic neurologic disease. The organization of the Coordinated Home Care program, the criteria for patient selection, and the issue of funding are reviewed. The impact of this program is examined in terms of its potential for better utilization of the Massachusetts General Hospital facilities, as well as the more appropriate coordination and use of existing health care resources in the community.
Collapse
|
49
|
|